Zealand Pharma

Spotlight – Nash in 2023 and beyond
Spotlight – Nash in 2023 and beyond
EP Vantage
NASH
Boehringer Ingelheim
Zealand Pharma
Akero Therapeutics
Axcella Health
Eli Lilly
Pfizer
Ionis Pharmaceuticals
Cascade
AstraZeneca
Gilead Sciences
Novo Nordisk
Ascletis Pharma
MediciNova
Flag link:
Boehringer's new data drop shows 19% weight loss for phase 2 obesity prospect
Boehringer's new data drop shows 19% weight loss for phase 2 obesity prospect
Fierce Biotech
Boehringer Ingelheim
obesity
clinical trials
Zealand Pharma
survodutide
Flag link:
Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trial
Zealand, Boehringer's drug meets main weight-loss goal in mid-stage trial
BioSpace
Boehringer Ingelheim
Zealand Pharma
obesity
clinical trials
BI 456906
Flag link:
Boehringer signals intent in obesity
Boehringer signals intent in obesity
EP Vantage
Boehringer Ingelheim
Zealand Pharma
obesity
clinical trials
BI 456906
Flag link:
Zealand Pharma reports data from Phase III short bowel syndrome trial
Zealand Pharma reports data from Phase III short bowel syndrome trial
Clinical Trials Arena
Zealand Pharma
clinical trials
glepaglutide
short bowel syndrome
Flag link:
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Diabetes Drug
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Diabetes Drug
Yahoo/Benzinga
Zealand Pharma
Novo Nordisk
Zegalogue
diabetes
hypoglycemia
Flag link:
Key data catalysts for the industry’s small players
Key data catalysts for the industry’s small players
EP Vantage
Intercept Pharma
Akero
NASH
Kymera
atopic dermatitis
Zealand Pharma
short bowel syndrome
Relmada
Verona
Anavex
Assembly Biosciences
Aldeyra
Flag link:
MannKind Acquires Wearable Insulin Device from Zealand Pharma
MannKind Acquires Wearable Insulin Device from Zealand Pharma
Medical Devices and Diagnostics Industry
MannKind
Zealand Pharma
V-Go
insulin
diabetes
devices
Medtech
Flag link:
Workforce Cuts Abound at Zealand Pharma, Merck and Orchard
Workforce Cuts Abound at Zealand Pharma, Merck and Orchard
BioSpace
Zealand Pharma
Merck
Orchard Therapeutics
layoffs
Flag link:
After spurning Sanofi for diabetes disappointment, Zealand nets FDA approval in severe hypoglycemia
After spurning Sanofi for diabetes disappointment, Zealand nets FDA approval in severe hypoglycemia
Endpoints
Zealand Pharma
Zegalogue
hypogylcemia
diabetes
Sanofi
Flag link:
Zealand acquires a struggling diabetes med-tech in push into US market
Zealand acquires a struggling diabetes med-tech in push into US market
Endpoints
Zealand Pharma
M&A
Valeritas
devices
diabetes
Flag link:
Zealand’s Severe Hypoglycemia Treatment Hits the Mark in Another Phase III Trial
Zealand’s Severe Hypoglycemia Treatment Hits the Mark in Another Phase III Trial
BioSpace
Zealand Pharma
hypoglycemia
dasiglucagon
HypoPal
Flag link:
Alexion adds to pipeline with two early-stage R&D deals
Alexion adds to pipeline with two early-stage R&D deals
BioPharma Dive
Alexion Pharmaceuticals
Affibody
Zealand Pharma
ABY-039
R&D
Flag link:
Zealand Pharma blueprints an $86M IPO on Nasdaq as it maneuvers its way into PhIII
Zealand Pharma blueprints an $86M IPO on Nasdaq as it maneuvers its way into PhIII
Endpoints
Zealand Pharma
IPO
NASDAQ
dasiglucagon
hypoglycemia
glepaglutide
short bowel syndrome
Flag link:
Sanofi's LixiLan Progresses
Sanofi's LixiLan Progresses
Yahoo/Zacks.com
Sanofi
LixiLan
insulin
Lantus
diabetes
Zealand Pharma
Lyxumia
Flag link:
Zealand Pharma, Eli Lilly sign obesity, diabetes research deal
Zealand Pharma, Eli Lilly sign obesity, diabetes research deal
Reuters
Eli Lilly
Zealand Pharma
obesity
diabetes
R&D
Flag link:
Zealand Pharma Announces GetGoal Duo 1 and GetGoal-L Phase III Data on Lixisenatide (Lyxumia(R))1 to be Presented at ADA
Zealand Pharma Announces GetGoal Duo 1 and GetGoal-L Phase III Data on Lixisenatide (Lyxumia(R))1 to be Presented at ADA
Yahoo/Global NewsWire
lixisenatide
Zealand Pharma
Sanofi
type 2 diabetes
diabetes
Flag link: